M. Swamivelmanickam, P. Venkatesan, G. Sangeetha
M. Swamivelmanickam1, P. Venkatesan2, G. Sangeetha3
1,2Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India.
3Department of Pharmaceutics, Krupanidhi College of Pharmacy, Bangalore, Karnataka, India.
Volume - 13,
Issue - 6,
Year - 2020
Loratadine, histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Administration of Loratadine through oral route is a challenge in children, who have difficulty to swallow tablets. In the present study, nine batches of Loratadine Mouth Dissolving tablets (MDTs) dosage form at the dose of 10 mg were formulated and evaluated. Results showed that thickness, weight variation, friability, hardness, and content uniformity of all five formulations were within the acceptable limits. But in the in-vitro dissolution study, formulation 7, 8 and 9 demonstrated better cumulative drug release than formulation 3 and 6. However, cumulative drug release of formulation 9 was comparable with innovator than formulation 3 and 6. Three month stability study of formulation 9 revealed that there were no significant change in physical parameters, drug content and dissolution profile. Hence the study concludes that Loratadine mouth dissolving tablets formulated using starch-1500 and microcrystalline cellulose (Formulation 9) showed better characteristics of mouth dissolving tablets.
Cite this article:
M. Swamivelmanickam, P. Venkatesan, G. Sangeetha. Preparation and Evaluation of Mouth Dissolving Tablets of Loratadine by Direct Compression Method. Research J. Pharm. and Tech 2020; 13(6):2629-2633. doi: 10.5958/0974-360X.2020.00467.9
1. Haria M, et al. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994; 48: 617–37.
2. Nehal siddiqui M D, Garima G and Pramod kumar S. A Short Review on “A Novel Approach in Oral Fast Dissolving Drug Delivery System and Their Patents, Advances in Biological Research 2011;5 (6): 291-303.
3. Kuchekar B S, Atul B C, Mahajan H S. (2003) Mouth dissolving tablets: a novel drug delivery system, Pharma Times. 2003; 35: 7-9.
4. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H, et al. Mirtazapine orally disintegrating tablet versus sertraline: A prospective onset of action study. J Clin Psychopharmacol 2003; 23:358-64.
5. Bankar GS and Rhodes CT (1996), Modern Pharmaceutics, 3rd edition, Marcel Dekker, Inc. New York, 1996, 668-669.
6. Nandgude TD, Saifee M, Bhise KS. Formulation and evaluation of fast disintegrating tablets of diphenhydramine tannate. Am J Pharm 2006; 1:41-5.
7. Bhupendra G.Prajapati, Bhaskar Patel. Formulation, Evaluation and Optimization of Orally Disintegrating Tablet of Piroxicam. International Journal of PharmTech Research (2010): 2(30); 1893-1899.
8. Anonymous. (2007), Indian Pharmacopoeia. Published by the Controller of Publication, Govt. of India, Ministry of Health and Family Welfare, New Delhi 2007, 1045.
9. Chaudhari PD, Chaudhari SP, Kolhe SR, Dave KV, More DM. Formulation and evaluation of fast dissolving tablets of famotidine. Indian Drugs. 2005; 42:641-9.
10. Mahajan HS, Patil SB, Gattani SG. Rapidly disintegrating tablets for elderly patients. Pharm Rev. 2005; 3: 49–5.
11. Lachman L, Lieberman HA. The theory and practice of Industrial Pharmacy, 3rd edition,Varghese Publishing House, Mumbai. 1991. 67-71, 183-184.
12. Bi Y,Sunada H,Yonezawa Y, Dayo K,Otsuka A, Iida K. Preparation and evaluation of compressed tablet rapidly disintegrating in oral cavity. Chem Pharm Bull (Tokyo) 1996;44: 2121-2127.